Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration
Launched by UNIVERSITY OF WISCONSIN, MADISON · Apr 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called geographic atrophy (GA), which is a form of age-related macular degeneration (AMD) that affects the retina, the light-sensitive layer at the back of the eye. The researchers want to see if certain imaging techniques can help identify areas of stressed cells in the retina, even before symptoms appear. By using a special imaging system called the OcuMet Beacon, the trial aims to evaluate patterns of increased autofluorescence, which could indicate areas of concern for patients with GA.
To participate in this trial, you need to be at least 50 years old and have a confirmed diagnosis of geographic atrophy due to AMD. The trial is open to both men and women of all races. Participants will undergo imaging of their eyes to gather important information about the condition. However, if you have certain other eye diseases, or if you cannot tolerate eye imaging, you may not be eligible. Overall, this study could help improve understanding and management of geographic atrophy in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 50 years or older and may be either male or female of any race
- • Established diagnosis of GA due to AMD
- • GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm2 to 17.5 mm2. GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
- • Willing to participate as evidenced by signing the written informed consent
- Exclusion Criteria:
- • Unable to tolerate ophthalmic imaging
- • Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
- • Presence of significant media opacity preventing adequate retinal imaging
- • Presence of concurrent retinal disease which may confound assessment
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Mihai Mititelu, MD, MPH
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported